Overweight and obesity cause 6,000 cancers a year in UK women

Following last week's report by the World Cancer Research Fund, evidence of the relevance of obesity to the risk of a wide range of cancers in UK women is published online by the BMJ today.

The study shows that overweight and obese women in the UK are at a higher risk of developing and dying from cancer. In fact, the researchers estimate that 5% of all cancers (about 6,000 annually) are attributable to being overweight or obese.

National survey data from the United Kingdom indicate that around 23% of all women in England are obese and 34% are overweight. Obesity is known to be associated with excess mortality from all causes combined, but less is known about its effects on cancer.

So Cancer Research UK researchers at Oxford University examined the relation between body mass index (BMI), cancer incidence and mortality in 1.2 million UK women aged between 50 and 64, who were recruited to the Million Women Study, a large cohort study of women in the UK.

Risks for all cancers, and for 17 specific types of cancer, were measured according to BMI and women were followed up for an average of 5.4 years for cancer incidence and 7 years for cancer mortality.

Women with a BMI of 25-29.9 were defined as “overweight” and women with a BMI of 30 or more as “obese,” in accordance with the World Health Organisation’s criteria.

Results were adjusted for factors such as age, socioeconomic status, smoking status, alcohol intake, physical activity, years since menopause, and use of hormone replacement therapy.

A total of 45,037 new cancers and 17,203 deaths from cancer occurred over the follow-up period.

Increasing body mass index was associated with an increased incidence of all cancers combined and for 10 out of the 17 specific types of cancer examined: endometrial cancer, adenocarcinoma (malignant tumor) of the oesophagus, kidney cancer, leukaemia, multiple myeloma, pancreatic cancer, non-Hodgkin’s lymphoma, ovarian cancer and, in some age groups, breast and colorectal cancer.

In general, the relation between body mass index and mortality was similar to that for incidence.

The data also show that menopausal status is a key factor in the relation between body mass index and risk of cancer among women, not only for those cancers that are known to be hormonally related, such as breast and endometrial cancer, but also for other common cancers not generally thought to be mediated by hormones, such as colorectal cancer and malignant melanoma.

Based on these results, the authors estimate that, among postmenopausal women in the UK, 5% of all cancers (about 6,000 annually) are attributable to being overweight or obese. But the impact of being overweight or obese on cancer risk was much bigger for some cancers than for others.

For endometrial cancer and adenocarcinoma of the oesophagus in particular, body mass index represents a major modifiable risk factor, as about half of all cases are attributable to overweight or obesity, they conclude.

In an accompanying editorial, Eugenia Calle of the American Cancer Society warns that the worldwide obesity epidemic shows no signs of abating, so insight into the mechanisms by which obesity contributes to the formation and progression of tumours is urgently needed, as are new approaches to intervene in this process.

Source: British Medical Journal

Related stories:

New breast imaging technology targets hard-to-detect cancers
Breast-specific gamma imaging (BSGI) is effective in the detection of cancers not found on mammograms or by clinical exam, according to a study presented today at the annual meeting of the Radiological Society of North America (RSNA).
Study supports new standard of treatment for women with advanced ovarian cancer
Results of a phase III, international randomized clinical trial demonstrate a new standard of care for treating advanced ovarian cancer that significantly reduces side-effects and post-operative deaths compared to the previously established treatment course. The study, presented at the 12th Biennial Meeting of the International Gynecologic Cancer Society (IGCS) in Bangkok in October, has a major impact on many countries where the new standard represents a more practical course of treatment.
HER2 levels may aid in treatment selection for metastatic breast cancer
Findings published in the December 1, 2008, issue of Clinical Cancer Research, a journal of the American Association for Cancer Research, show lapatinib benefits women with HER2-positive breast cancer, while women with HER2-negative breast cancer or those who express EGRF alone derive no incremental benefit. In addition, a misclassification of metastatic breast cancer patients by as much as 10 percent prevents some people from receiving optimal therapy.
Ovarian cancer subtypes are different diseases: Implications for biomarker studies
In a new analysis of tissue biomarkers expressed in ovarian cancer samples, published by PLoS Medicine, David Huntsman and his colleagues from Vancouver General Hospital suggest that substantial differences exist between ovarian cancer subtypes which should be reflected in patient management. Although ovarian cancer is not the most common gynecologic cancer in women, the disease contributes a substantial burden of mortality in part because symptoms are nonspecific and the disease presents late in its course.
Study unmasks how ovarian tumors evade immune system
Scientists at Johns Hopkins have determined how the characteristic shedding of fatty substances, or lipids, by ovarian tumors allows the cancer to evade the body's immune system, leaving the disease to spread unchecked. Ovarian cancer is considered to be one of the most aggressive malignancies, killing more than 70 percent of diagnosed women within five years, including an estimated 15,000 this year.
Dual-head gamma camera increases ability to detect breast tumors not seen on mammography
A dual-headed dedicated gamma camera used during molecular breast imaging (MBI) can accurately detect small breast tumors less than 2 cm in size, according to a study performed at the Mayo Clinic in Rochester, MN.
Eating eggs when pregnant affects breast cancer in offspring
A stunning discovery based on epigenetics (the inheritance of propensities acquired in the womb) reveals that consuming choline—a nutrient found in eggs and other foods—during pregnancy may significantly affect breast cancer outcomes for a mother's offspring. This finding by a team of biologists at Boston University is the first to link choline consumption during pregnancy to breast cancer. It also is the first to identify possible choline-related genetic changes that affect breast cancer survival rates.
Annual report finds declines in cancer incidence and death rates
A new report from the nation's leading cancer organizations shows that, for the first time since the report was first issued in 1998, both incidence and death rates for all cancers combined are decreasing for both men and women, driven largely by declines in some of the most common types of cancer. The report notes that, although the decreases in overall cancer incidence and death rates are encouraging, large state and regional differences in lung cancer trends among women underscore the need to strengthen many state tobacco control programs. The findings come from the "Annual Report to the Nation on the Status of Cancer, 1975-2005, Featuring Trends in Lung Cancer, Tobacco Use and Tobacco Control", online Nov. 25, 2008, and appearing in the Dec. 2, 2008, Journal of the National Cancer Institute.

News discussion:

Medicine & Health news